Precision Cancer Consortium

??? Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives? ? Immunotherapy and targeted treatment in thoracic oncology are revolutionizing care, particularly for patients with non-squamous non-small cell lung cancer. ?? ?? ? With the growing complexity of predictive biomarkers, next-generation sequencing (NGS) is now essential— using circulating free DNA, whether that be from tissue or liquid biopsies (LBx).?? While LBx offers a non-invasive approach for biomarker assessment and aligns with international guidelines, its integration into routine clinical practice remains limited in Europe, especially in France.?????? ?? Optimized algorithms could enhance adoption of NGS, improving molecular biomarker testing for advanced cases.? Access this comprehensive review from Prof Paul Hofman (September 2024) which explores the opportunities, limitations, and future perspectives using the link to abstract below: ?? https://lnkd.in/egKaJab8 #LungCancer #Oncology #PrecisionMedicine #NGS #LiquidBiopsy? ---?? ? Ref: PCC-124? February 2025? ??? The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.???

?? United in our message, ?? Unique in our stories. Today is #WorldCancerDay - a day to share and unite. The PCC brings together skilled and dedicated diagnostic professionals, from seven pharmaceutical companies, all focused on accelerating global access to comprehensive genomic profiling, and seeking to improve outcomes for patients with cancer. Our unique collaboration presents an opportunity for efficiencies and expanded impact beyond what any one of our companies could accomplish alone. Our vision is to make precision oncology and Comprehensive Genomic Profiling (CGP) the new normal. Our efforts today will hopefully lead to a healthier tomorrow. ?? #WorldCancerDay #precisionmedicine 1?? in 5?? people will develop cancer during their lives ?? The cost of cancer care has an annual economic impact of over $1 trillion (Reference: World Health Organization) PCC-123 February 2024 The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.

Precision oncology and Comprehensive Genomic Profiling (CGP) has the potential to improve outcomes for cancer patients, but despite ongoing efforts, access remains limited. ?? A key hurdle to accessing CGP is patients’ inability to be tested at all disease stages and across all tumor types. Understanding: ?? national and regional policies, ?? key influencers, ?? challenges, ?? and opportunities is crucial to facilitate implementation of CGP into routine practice for all patients and to establish biomarker testing as central to complete diagnosis, regardless of disease stage or tumor type. Taking Spain ???? as a pilot country, PCC, Avalere Health and HiTT - Health Innovation Technology Transfer have initiated a new project to map barriers and recommend actions to improve patient access to CGP, with the aim of eventually providing all patients access to CGP at the time of their initial diagnosis (solid tumors), regardless of tumor type. By focussing on each of the autonomous communities in Spain the project’s intention is to identify common issues and make specific recommendations to address them. This video summarises the ambitions for project. --- Ref: PCC-120 January 2025 ?? The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.?

As we prepare to celebrate our third year of operation, PCC is proud to reflect on the notable milestones achieved in 2024. Across numerous successfully executed projects, we've made significant progress towards our mission. Looking ahead to 2025, we are excited to build on this momentum. With several major projects nearing completion, we’re ready to use this strong foundation as a launchpad for maximising patient impact. ?? Our vision remains clear: to make precision oncology and comprehensive genomic profiling the new normal. Together, we can turn this vision into reality. --- Ref: PCC-119 January 2025 ?? The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.?

Did you attend #ISLB2024 During November’s International Society of Liquid Biopsy annual conference, PCC continued their drive to raise awareness of liquid biopsy (LBx) and its potential to expand global access to comprehensive genomic profiling (CGP) by sponsoring an industry symposium with leading experts in the field. The symposium entitled “Expanding access and adoption of liquid biopsy (LBx) in routine clinical care: Expert insights, practical solutions, and your chance to join the conversation” featured: ?? Simon Heeke (MD Anderson Cancer Center) ?? Bruna Pellini (H. Lee Moffitt Cancer Center and Research Institute, Morsani College of Medicine) ?? Paul Hofman (Pasteur Hospital, Sophia Antipolis University) ?? Thivyan Thayaparan (PCC member and External Innovation & Scientific Strategy Director, GSK) Nearly 150 attendees (comprising diagnostics and pharma / biotech professionals, healthcare professionals (HCPs) and researchers) were actively involved in the discussions during the fire-side chat, which included interactive polling and audience questioning.? ? The highlights from the polling include: 1?? Do you think that you have received adequate training or education on understanding liquid biopsies and interpreting their results? (n=54) ??? 33% answered ‘insufficient training’ 2?? What are specific challenges that you have experienced in adopting liquid biopsies? (n=60) ????55% answered ‘reimbursement’ 3?? What type of initiative do you think can most improve access to liquid biopsy? (n=54) ????31% answered ‘the need to improve HCP education’ These insights will help guide future PCC endeavours in the LBx arena as they negotiate real-world challenges and seek solutions surrounding LBx access and adoption. Tyler Marquart, PhD, Ramin Dowlati, Alexander Yarunin, Zebin (Sarah) Wang, Tina Wang --- Ref: PCC-118 December 2024? ?? The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.?

At the recent Advancing Precision Medicine congress, Gabriele Allegri (VP of Global Commercial Precision Medicine Johnson & Johnson Innovative Medicine and PCC Vice Chair) kicked-off day 2 with a keynote presentation entitled “Accelerating Precision Medicine Beyond Oncology”. ? Gabriele’s key talking points are summarised in the poster below. The cornerstone of his presentation was partnerships and collaboration, which fully aligns with PCC’s mission to foster collaboration and improve global patient access to comprehensive genomic testing in routine care and clinical trials. ?? If you would like to contribute to this important mission through a collaborative project with PCC in 2025, please click on the link to visit the PCC website and submit a collaboration proposal form. A member of the PCC will then be in touch to discuss the proposal with you. ?? https://lnkd.in/e-RrNFcd --- Ref: PCC-116 December 2024? ?? The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.?

Let’s continue the conversation…???? During Novembers Advancing Precision Medicine congress, Nicole St Jean (PCC Chair) and panelists Nicole Sheahan (Global Colon Cancer Association), Phillip G. Febbo, MD (Veracyte) and Lauren C. Leiman (BLOODPAC) discussed 6?? items that are blocking liquid biopsy uptake in global markets: 1?? Perceptions around liquid vs tissue biopsy, 2?? Engaging the right stakeholders in the decision-making process, 3?? The important role of industry partners, 4?? Access challenges, 5?? Ongoing activities making an impact, and 6?? Collecting data in under-represented populations More info around these conversations can be found in the carousel (PDF) below. 2 questions to our followers: ? What one item is preventing liquid biopsy (LBx) uptake in your setting?? ? If there is one item you could fix to improve LBx use, what would it be?? Let’s continue the conversation, with a bid to showcase solutions at future Precision Medicine events in 2025. Kudos also to the organizers at Advancing Precision Medicine , in particular Deanna Russell and team in creating and executing a well-run, and much needed Precision Medicine-focussed congress. --- Ref: PCC-112 November 2024? ?? The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.?

Can't wait to meet DeciBio and Tina Wang + team! See you in Denver. #ISLB2024 #LiquidBiopsy

Attending #ISLB24 in Denver USA? ???? PCC are pleased to invite you to attend a sponsored symposium at the upcoming International Society of Liquid Biopsy (ISLB) congress entitled “Expanding access and adoption of liquid biopsy in routine clinical care: Expert insights, practical solutions, and your chance to join the conversation”. ?? This symposium will take place on Saturday 23rd November,12:45 local time ?? in the Adams B meeting room. Come along to meet some of the PCC team (Thivyan Thayaparan) and our panel featuring Simon Heeke, Paul Hofman and Bruna Pellini as we hear what the experts have to say about improving patient access to CGP and what we can all do to make a difference. PCC look forward to seeing you in Denver! #LiquidBiopsy #ISLB24 --- Ref: PCC-111 November 2024? ?? The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.?

PCC would like to raise the awareness of an important paper published in August 2024 addressing gaps in cancer treatment and diagnosis within European health services. The online paper (DeGruyter. com), focusses specifically on: 1?? discrepancies between clinical guidelines and policy guidelines, and 2?? how the under-utilization of advanced diagnostic techniques recommended by medical societies contributes to missed opportunities for improving patient outcomes. A summary infographic of the paper is below, with a link to the online abstract (full article is behind a paywall). Ref: PCC-092 May 2024 --- The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bayer, GSK, Johnson & Johnson, Lilly, Novartis, and Roche, at the time of writing.